Rakuten Securities Inc. Has $312,000 Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

Rakuten Securities Inc. lifted its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 696.9% during the fourth quarter, Holdings Channel reports. The firm owned 7,499 shares of the company’s stock after purchasing an additional 6,558 shares during the quarter. Rakuten Securities Inc.’s holdings in Moderna were worth $312,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Knuff & Co LLC grew its stake in Moderna by 5.4% in the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock valued at $316,000 after purchasing an additional 244 shares in the last quarter. Allworth Financial LP grew its stake in Moderna by 17.3% in the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after purchasing an additional 281 shares in the last quarter. Howard Capital Management Inc. grew its stake in Moderna by 3.1% in the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock valued at $416,000 after purchasing an additional 297 shares in the last quarter. Larson Financial Group LLC grew its stake in Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares in the last quarter. Finally, Empowered Funds LLC boosted its stake in shares of Moderna by 6.6% during the 3rd quarter. Empowered Funds LLC now owns 5,199 shares of the company’s stock worth $347,000 after acquiring an additional 322 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on MRNA shares. JPMorgan Chase & Co. set a $45.00 price objective on Moderna in a research report on Friday, February 14th. Argus cut Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Morgan Stanley cut their price objective on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 15th. Piper Sandler reissued an “overweight” rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. Finally, Evercore ISI set a $50.00 price objective on Moderna in a research report on Friday, February 14th. Four investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $60.63.

Moderna Trading Down 6.1 %

NASDAQ:MRNA opened at $33.76 on Wednesday. The company has a market cap of $13.03 billion, a PE ratio of -3.64 and a beta of 1.86. Moderna, Inc. has a twelve month low of $29.25 and a twelve month high of $170.47. The company’s 50 day moving average is $36.38 and its two-hundred day moving average is $48.11.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.